Recent performance snapshot
Eli Lilly (LLY) has seen mixed short term moves, with the stock down slightly over the past day and roughly flat over the past week, while posting gains over the past month and over the past 3 months.
See our latest analysis for Eli Lilly.
Looking beyond the past week, Eli Lilly’s 10.47% 1 month share price return contrasts with a modest decline year to date, while its 1 year total shareholder return of 42.74% points to stronger longer term momentum.
If Eli Lilly’s recent moves have you thinking about where healthcare and AI intersect, it could be worth scanning a wider field through our 39 healthcare AI stocks
With Eli Lilly trading at $1,064.15 alongside an intrinsic value estimate implying a discount and a value score of 2, you need to ask if this is a genuine opportunity or if markets are already pricing in future growth.
Most Popular Narrative: 28% Undervalued
According to AHaron’s narrative, Eli Lilly’s fair value of $1,477.03 sits well above the last close at $1,064.15, framing the stock as materially undervalued on that view.
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet.
Want to see what kind of revenue expansion, margin profile, and future earnings multiple are baked into that fair value? The narrative leans on ambitious growth, rich profitability, and a premium valuation that still aims to justify a much higher price tag.
Result: Fair Value of $1,477.03 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on obesity drug demand and pricing not disappointing, and on key pipeline assets like retatrutide avoiding safety or efficacy setbacks that would unsettle expectations.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Another way to look at valuation
While the user narrative leans on growth assumptions and fair value estimates, the market is also putting a steep price on Eli Lilly today. The stock trades on a P/E of 37.5x, above both the estimated fair ratio of 35.2x and the peer average of 23.1x. This points to meaningful valuation risk if sentiment cools. How comfortable are you paying that kind of premium for this story?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of confidence and concern in this story, it makes sense to look at the full picture yourself and move quickly if needed with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas?
If Eli Lilly has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that could fit your goals and risk comfort.
- Spot potential bargains early by scanning 46 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them.
- Prioritise resilience and sleep-at-night holdings through the 63 resilient stocks with low risk scores that highlights companies with lower historical risk scores.
- Hunt for less crowded opportunities using the screener containing 22 high quality undiscovered gems that surfaces financially solid stocks still flying under most investors’ radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com